Calithera Biosci Com (CALA) |
|
2.7 0.01 (0.37%)
|
03-07 04:12 |
|
Open: |
2.69 |
Pre. Close: |
2.69 |
|
High:
|
2.72 |
Low:
|
2.3838 |
|
Volume:
|
1,474,953 |
Market Cap:
|
191M |
|
|
|
|
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.726 - 2.744 |
2.744 - 2.761 |
|
Low:
|
2.34 - 2.361 |
2.361 - 2.379 |
|
Close:
|
2.664 - 2.701 |
2.701 - 2.734 |
|
Technical analysis |
as of: 2021-03-05 5:05:57 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 3.47  One year: 3.90 |
| Support: |
Support1: 2.38 Support2: 1.98 |
| Resistance: |
Resistance1: 2.97 Resistance2: 3.34 |
| Pivot: |
2.97 |
| Moving Average: |
MA(5): 2.80 MA(20): 3.03
MA(100): 3.84 MA(250): 4.52 |
| MACD: |
MACD(12,26): -0.15 Signal(9): -0.13 |
| Stochastic oscillator: |
%K(14,3): 18.58  %D(3): 17.62 |
| RSI: |
RSI(14): 31.93 |
| 52-week: |
High: 8.18 Low: 2.38 Change(%): -51.9 |
| Average Vol(K): |
3-Month: 180904 10-Days: 130430 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.CALA has closed above bottom band by 9.5%. Bollinger Bands are 47.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to CALA's normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Tue, 02 Mar 2021
Calithera to Present at the H.C. Wainwright Virtual Global Life Sciences 2021 Conference - Yahoo Finance
Mon, 22 Feb 2021
Calithera to Participate in the 10th Annual SVB Leerink Global Healthcare Conference - Yahoo Finance
Mon, 22 Feb 2021
Calithera Biosciences, Inc. (NASDAQ:CALA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Wed, 13 Jan 2021
Implied Volatility Surging for Calithera Biosciences (CALA) Stock Options - Yahoo Finance
Mon, 04 Jan 2021
Why Calithera Biosciences Stock Is Plunging Today - Motley Fool
Mon, 28 Dec 2020
Our Take On Calithera Biosciences' (NASDAQ:CALA) CEO Salary - Yahoo Finance
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
71 |
| Shares Float (M) |
62 |
|
% Held by Insiders
|
0.72 |
|
% Held by Institutions
|
81.73 |
|
Shares Short (K)
|
3,570 |
|
Shares Short P. Month (K)
|
2,020 |
Stock Financials |
|
EPS
|
-1.375 |
|
EPS Est This Year
|
-0.810 |
|
EPS Est Next Year
|
-1.050 |
|
Book Value (p.s.)
|
1.740 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-38.8 |
|
Return on Equity (ttm)
|
-73.4 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
-1.081 |
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-1.287 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-80 |
|
Levered Free Cash Flow (M)
|
-47 |
Stock Valuations |
|
PE Ratio
|
-1.96 |
|
PEG Ratio
|
|
|
Price to Book value
|
1.55 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-2.39 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
